Quarterly Activities Report and 4C
Avecho Biotechnology Limited (ASX:AVE) has today released its Quarterly Activities Report and 4C for the quarter ended 30 June 2021.
The continued development of our soft-gel CBD product has been the main focus for the Company during this period, resulting in the achievement of a number of key milestones:
- CBD soft-gel capsule design finalised by Catalent Pharma Solutions
- TGA meeting activities planned to gain feedback on CBD program
- Recruitment on the CACOS observational clinical trial continued – 130 patients were enrolled in the trial by the end of June.
Independent of our CBD program, Avecho also made progress in the animal health space, with our potential partner AB Vista looking at opportunities to take our TPM® technology to the animal feed market.
Our cash balance at the close of the quarter was $4.8m.
Avecho remains committed to its R&D programs, while continuing to demonstrate prudent cash management and adapt its operational policies and procedures in line with COVID-19 mitigation measures.